338 results on '"Warren, R. B."'
Search Results
2. Drug survival and safety of biosimilars and originator adalimumab in the treatment of psoriasis: a multinational cohort study
3. AB1099 SUSTAINED EFFICACY OF BIMEKIZUMAB TREATMENT ASSESSED USING COMPOSITE DISEASE ACTIVITY MEASURES IN PATIENTS WITH PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE OR INTOLERANCE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN LABEL EXTENSION UP TO 1 YEAR
4. POS0231 SUSTAINED EFFICACY AND SAFETY OF BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: RESULTS FROM THE PHASE 3 BE COMPLETE STUDY AND ITS OPEN-LABEL EXTENSION UP TO 1 YEAR
5. POS1537 BIMEKIZUMAB EFFICACY AND SAFETY IN BIOLOGIC DMARD-NAÏVE PATIENTS WITH PSORIATIC ARTHRITIS WAS CONSISTENT WITH OR WITHOUT METHOTREXATE: 52-WEEK RESULTS FROM THE PHASE 3 ACTIVE‑REFERENCE STUDY BE OPTIMAL
6. AB0938 SAFETY PROFILE OF BIMEKIZUMAB AT WEEK 16 IN PATIENTS WITH AXIAL SPONDYLOARTHRITIS AND PSORIATIC ARTHRITIS: RESULTS FROM FOUR PLACEBO-CONTROLLED PHASE 3 STUDIES
7. Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis
8. Tunnel ring design, development, testing and manufacture for the London Water Ring Main
9. Secukinumab improves the quality‐of‐life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised open‐label study (SIGNATURE)
10. AB0890 Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Moderate to Severe Plaque Psoriasis: 52-Week Efficacy Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials
11. OP0255 BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS AND AN INADEQUATE RESPONSE TO TUMOUR NECROSIS FACTOR INHIBITORS: 16-WEEK EFFICACY & SAFETY FROM BE COMPLETE, A PHASE 3, MULTICENTRE, RANDOMISED PLACEBO-CONTROLLED STUDY
12. LB0001 BIMEKIZUMAB IN BDMARD-NAIVE PATIENTS WITH PSORIATIC ARTHRITIS: 24-WEEK EFFICACY & SAFETY FROM BE OPTIMAL, A PHASE 3, MULTICENTRE, RANDOMISED, PLACEBO-CONTROLLED, ACTIVE REFERENCE STUDY
13. POS1046 DEUCRAVACITINIB LONG-TERM EFFICACY AND SAFETY IN PLAQUE PSORIASIS: 2-YEAR RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM
14. Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINE‐2 and ‐3
15. A novel mutation in IL36RN underpins childhood pustular dermatosis
16. Barriers to the prescription of systemic therapies for moderate-to-severe psoriasis––a multinational cross-sectional study
17. Demographics and disease characteristics of patients with psoriasis enrolled in the British Association of Dermatologists Biologic Interventions Register
18. Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV, multicenter, randomized, controlled, prospective study
19. Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions
20. Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINE-2 and AMAGINE-3
21. Five-year efficacy and safety of tildrakizumab in patients with moderate to severe psoriasis who respond at week 28: pooled analyses of two randomised phase 3 clinical trials (reSURFACE 1 and reSURFACE 2)
22. POS1042 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY
23. POS1022 BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDY
24. In search of oral psoriasis
25. Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients
26. Genotyping of immune-related genetic variants identifies TYK2 as a novel associated locus for idiopathic inflammatory myopathies
27. A consensus report on appropriate treatment optimization and transitioning in the management of moderate-to-severe plaque psoriasis
28. Psoriatic arthritis screening tools: study design and methodologic challenges – reply from authors
29. Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis
30. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge):Results from a phase 3, randomised, open-label, efficacy assessor-blinded clinical trial
31. Long-term efficacy and safety of tildrakizumab for moderate-to-severe psoriasis:pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2) through 148 weeks
32. An evaluation of dermatology patients shielding during the COVID‐19 outbreak
33. The risk of postoperative complications in patients with psoriasis or psoriatic arthritis on biological therapy: O13
34. Chronic inflammatory demyelinating polyneuropathy during infliximab therapy for psoriasis: 01
35. Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST study)
36. An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of the REL gene
37. Time for a ‘joint’ approach?
38. Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C
39. Cutaneous Mycobacterium haemophilum infection in a patient receiving infliximab for psoriasis
40. Clinical and immunological aspects of late-onset psoriasis: O13
41. The British Association of Dermatologists’ Biologic Interventions Register (BADBIR): design, methodology and objectives
42. Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy
43. Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland
44. Psoriasis comorbidities: a worldwide problem?
45. Whatʼs new in psoriasis? An analysis of guidelines and systematic reviews published in 2009–2010
46. Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course
47. A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21
48. Re. major life-changing decisions and cumulative life course impairment
49. Certolizumab Pegol for Treatment of Plaque Psoriasis: Pooled Three-Year Efficacy Outcomes from Two Phase 3 Trials (CIMPASI-1 and CIMPASI-2)
50. Durable Efficacy of Certolizumab Pegol Dosed at 400 mg Every Two Weeks Over 128 Weeks in Patients with Plaque Psoriasis Enrolled in Three Phase 3 Trials (CIMPASI-1, CIMPASI-2 and CIMPACT)
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.